| Latest Forum Topics / ULTRAGREEN AI USD Last:1.39 -- |
 Post Reply
|
|
AA
|
|||||||||||||||||||
|
n3wbie
Elite |
29-Apr-2026 00:06
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Any followers of this stock at all? One of the few rare healthcare stocks that has a good growth story, > 80% gross margins and solid ROE of > 35% yet continues to trade under ipo price. Is market mispricing the stock or is it another case of good stock listed on the wrong exchange? | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
Joelton
Supreme |
08-Apr-2026 11:04
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Tan of DBS maintains US$2 target price on UltraGreen.ai reaction to tariffs a chance to accumulate Amanda Tan of DBS Group Research has maintained her " buy" call and US$2 target price on UltraGreen.ai as she believes that recent price reactions to US tariffs on pharmaceuticals is uncalled for and that the current weakness is an opportunity for investors to accumulate. From the recent peak of US$1.86 on Feb 23, UltraGreen.ai shares have dipped by more than a fifth. The Trump Administration has recently issued an executive order imposing a 100% tariff on patented pharmaceutical products imported into the United States unless manufacturers agree to government drug pricing arrangements or commit to producing the drugs domestically. Generic pharmaceutical products, biosimilars, and associated ingredients are not subject to tariffs at this time though this will be reassessed in one year, points out Tan in her April 7 note. " The implications for UltraGreen.ai should be limited as indocyanine green is classified as a generic drug and therefore falls under the current tariff exemption," says Tan, referring to UltraGreen.ai' s key product. " Even if the tariff regime were eventually extended to include generics, we believe demand for indocyanine green would remain relatively price inelastic and Ultragreen.ai should be able to pass on any tariff related cost increases to customers," she says. To put things into better perspective, Tan points out that the indocyanine green dye sold by UltraGreen.ai represents only a small portion of overall surgical procedure costs, with an average selling price of about US$90 to US$200 per vial, while its use improves visualisation during surgery and reduces the risk of complications. " As such, surgeons are unlikely to materially reduce usage even if prices rise," she reasons. In addition, UltraGreen.ai' s indocyanine green vials and kits for the Americas are packaged, serialised and labelled at the Praxis facility in Michigan, and not imported from other countries, which could thus provide an additional mitigating factor against potential tariffs. " In our view the continued adoption of fluorescence guided surgery, supported by a growing body of clinical evidence and expanding regulatory approvals across multiple markets, should remain the key driver of demand for UltraGreen.ai&rsquo s products," says Tan. Trading at just 19x FY2026 and 16x FY2027 earnings, Tan believes this counter is now changing hands at an attractive valuation level. UltraGreen.ai shares gained 2.1% to trade at US$1.46 as at 1.53pm. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
Joelton
Supreme |
07-Apr-2026 11:12
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
UltraGreen.ai' s ID Nicky Tan raises stake after buying shares at below IPO price Tan Ng Kuang, an independent director of UltraGreen.ai, has added to his stake in medical company over recent two market days. Better known as Nicky Tan, he is known for leading a boutique corporate advisory firm nTan Corporate Advisory. On March 31, he paid an average of US$1.445 each for 20,000 shares. On April 6, he paid an average of US$1.43 for another 10,000 shares. This gives him a total stake of 80,200 shares. Despite announcements that it has received more regulatory greenlights to enter new markets, UltraGreen.ai shares weakened in recent days, dropping to as low as US$1.43 on April 6, from the recent peak of US$1.86 on Feb 23. Analysts covering this counter had earlier signalled that they expect UltraGreen.ai' s margins to come under some pressure as the company ramps up hiring so as to develop new markets and better organise its systems. UltraGreen.ai' s IPO last December was priced at US$1.45 per share. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
JurongW
Elite |
28-Mar-2026 13:23
Yells: "Earnings give weight, Chart give wings" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Ultragreen AI&rsquo s recent drop from 1.86 to 1.47 appears to be driven by short-term market sentiment and profit-taking rather than a specific negative event. In fact, analysts suggest the company could benefit from competitor disruptions, meaning the decline may be more technical than fundamental. 📉 Stock Price Movement
🔎 Possible Reasons for the Drop
🚀 Positive Catalysts Ahead
📊 Quick Comparison Table
⚠ ️ Risks to Watch
👉 Bottom Line : The drop looks more like a technical correction than a fundamental weakness. With analysts projecting upside and a competitor facing disruption, Ultragreen AI could rebound if it executes well. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
LexLut88
Member |
28-Mar-2026 12:00
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
what is happending to this share ? drop until so bad . so many panic seller ? | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
Joelton
Supreme |
19-Mar-2026 12:36
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
UltraGreen.ai to benefit from disruption at rival pricing power and volume to drive earnings ahead: UOBKH and Citi
A recent cyberattack suffered by US medtech firm Stryker Corp, which competes with UltraGreen.ai in selling indocyanine green (ICG) dye used in surgeries, could be a near-term boost for the latter, according to UOB Kay Hian analysts John Cheong, Heidi Mo and Tang Kai Jie.
Earlier this month, Stryker Corp was reportedly hit by an Iran-linked hacking group, disrupting order processing.
Potential disruptions to order processing or fulfilment, particularly for consumables such as the ICG, could drive hospitals to alternative suppliers to avoid procedural delays.
" Given UltraGreen&rsquo s dominant share of around 83% of the US ICG vial market, the company is well-positioned to capture incremental demand during this period as healthcare providers prioritise supply reliability," suggest the analysts in their March 18 report.
That aside, UltraGreen recently announced it has won regulatory approvals in India, Thailand, the Philippines and Bangladesh, thereby expanding its addressable market to 45 countries and territories.
" These milestones reinforce UltraGreen&rsquo s APAC expansion strategy, strengthening its regional presence and positioning the company to capture rising demand from growing surgical volumes and wider clinical adoption of ICG," says UOB Kay Hian.
The company, with US$173 million in net cash and an operating cash flow of US$53 million in FY2025, is deemed to have ample dry powder to drive its expansion. In the most recent FY2025, revenue increased by 24% y-o-y to US$142 million, and patmi increased by 14% to US$63.8 million.
This current FY2026, UltraGreen is guiding for revenue of US$170 to US$190 million, with additional sales from more markets, even as it maintains its pricing power.
UOB Kay Hian is projecting earnings to grow at a 30% CAGR between FY2025 and FY2028.
The brokerage is keeping its " buy" call and US$1.95 target price, which is pegged to 26x FY2026 earnings, which is a discount of 16% to 31x fetched by its peers. " The company&rsquo s strong earnings growth, high margins, and improved price discovery should support a valuation re-rating," say the analysts.
Separately, Citi Research has initiated coverage on UltraGreen with a " buy" call and slightly higher target price of US$2. Citi likes this counter for its " high-growth profile" , with revenue between FY2022 and FY2025 growing at a 42% CAGR and FY2025 net margin reaching 53%.
Citi notes that UltraGreen is able to command higher prices even as volume grows. In FY2022, the average ICG was sold at US$70.3 per vial. In the subsequent years, the selling price increased steadily to first, US$84.5, then US$123.7 and finally US$139.3 in FY2025.
" We see further room to raise prices given UltraGreen&rsquo s dominance in global ICG space and relatively low cost of ICG" as part of overall surgery costs," says Citi.
This coming FY2027, Citi expects further revenue boost and improving gross margins as well with the launch of the UltraGreen Data Platform, which is designed to offer real-time, quantitative perfusion assessment and enhance decision-making in surgeries aided by the use of ICG.
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
JurongW
Elite |
18-Mar-2026 16:11
Yells: "Earnings give weight, Chart give wings" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
UOB Kay Hian - Set To Benefit From Multiple Positive Developments Highlights The recent cyberattack on Stryker provides a near-term opportunity for UltraGreen, as it could potentially increase demand for UltraGreen&rsquo s ICG vials. UltraGreen continues to build momentum in APAC, with several regulatory approvals obtained, supported by a strong net cash position. UltraGreen is trading at an attractive PE of 20x 2026F, 35% discount vs peers. Maintain BUY with an unchanged target price of US$1.95. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
Joelton
Supreme |
14-Mar-2026 11:28
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Margins may dip but UltraGreen.ai poised for more growth with more regulatory approvals UltraGreen.ai, a global market leader in the sale of indocyanine green (ICG) used in surgeries, reported FY2025 ended Dec 31, 2025 earnings of US$75.6 million ($96.9 million) for its first financial report card since its IPO last December, an increase of 35% over the preceding FY2024. Revenue in the same period was up 24% to US$142.4 million, driven by a 14% increase in the volume of vials shipped and a 17% increase in average selling price. The company maintained its gross margin at 85%. Its adjusted ebitda increased by 26% and its operating profit by 27%, reaching US$89.4 million and US$84.2 million, respectively, which the company says indicates strong operating performance. Its net profit after tax, before exceptional items, meanwhile, was up 14% to US$63.8 million. The one-offs included a disposal gain of US$23.7 million, a US$8.5 million tax provision, US$3.4 million in impairment charges, a loss on disposal of a non-core intangible asset and other charges. CEO Ravinder Sajwan calls FY2025 &ldquo a significant milestone&rdquo for the company with its IPO last December. He expects the company to continue delivering strong operational and financial growth, with FY2026 revenue between US$170 million and US$190 million. &ldquo This outlook is driven by underlying business expansion, the full-year impact of pricing initiatives implemented in FY2025, and further penetration into new markets,&rdquo says Sajwan. Amanda Tan of DBS Group Research, in her post-results note, says the &ldquo structural growth story&rdquo of UltraGreen remains unchanged, supported by continued ICG adoption, the full-year impact of prior increases in average selling price and further geographic expansion. UltraGreen&rsquo s revenue guidance is broadly in line with Tan&rsquo s US$178 million estimate. Tan, citing management, says the company&rsquo s guidance assumes a roughly equal split between volume gains and higher selling prices. Tan adds that there are no price increases planned for the US market in FY2026, while non-US markets are to see some &ldquo negligible&rdquo price increases, largely due to contractual price adjustments. &ldquo Thus far, orders year to date are on track to meet guidance,&rdquo she adds. However, Tan flags that the company is making further investments, which will incur additional costs. UltraGreen, she says, is increasing its headcount to 102 from 70 last year, in areas such as regulatory compliance and software, to accelerate business expansion, scale imaging systems and commercialise its data systems platform. &ldquo While this may temper near-term margins, we view it as strategically important to sustain long-term growth,&rdquo says Tan, who is keeping her &ldquo buy&rdquo call on this stock. Tan also notes that UltraGreen&rsquo s clinical and regulatory momentum continues to strengthen, which will presumably help reinforce its structural growth trajectory and wider use. She says the industry backdrop for Ultragreen remains favourable, with more than 20,000 peer-reviewed publications and over 780 clinical trials as of the end of 2025, validating ICG&rsquo s safety and expanding its clinical utility. On March 12, the company announced it had received regulatory approval in India, Thailand, the Philippines and Bangladesh. This means its products can now be sold in 45 territories, up from 35 in 2024. While Tan has kept her &ldquo buy&rdquo call on this counter, she has lowered her target price from US$2.05 to US$2. Her valuation multiple of 26x FY2026 earnings remains, but she has lowered her forecasts for FY2026 and the coming FY2027 by 3% to account for higher costs from a larger headcount and other spending. Similarly, the UOB Kay Hian team of analysts, John Cheong, Heidi Mo and Tang Kai Jie, have slightly trimmed their target price for the same reason: higher upfront costs that will eat into the bottom line. From US$2, they now figure the stock is worth US$1.95. That said, they remain bullish on this stock. &ldquo We expect UltraGreen to maintain strong pricing power, supported by its market leadership and the relatively low cost of ICG as a percentage of overall surgical expenses.&rdquo Coupled with higher usage volumes, the UOB Kay Hian analysts project revenue between FY2025 and FY2028 to grow at a CAGR of 20% and earnings at 30% over the same period, thanks to &ldquo strong industry tailwinds&rdquo . Following the company&rsquo s IPO, Hsieh Fu Hua, one of its independent directors and former CEO of the Singapore Exchange, bought shares in two tranches at US$1.39 and US$1.44 were share. Hsieh joins existing investors, including Temasek&rsquo s 65 Equity Partners and also UltraGreen chairman Kwa Chong Seng, a former SGX chairman. UltraGreen&rsquo s IPO was sold at US$1.45. With proceeds from the IPO, the company has an ample US$173 million in net cash to serve as dry powder for future expansion. &ldquo This provides ample capacity for UltraGreen to fund expansion and deepen market penetration,&rdquo state the UOB Kay Hian analysts. In deriving their target price of US$1.95, the UOB Kay Hian analysts have also applied the same valuation multiple of 26 times FY2026 earnings, which they point out represents a 20% discount to the 32 times average valuation of industry peers. They explain that the discount reflects UltraGreen&rsquo s limited trading history and research coverage, which should improve as its track record strengthens. Cheong, Mo and Tang point out that the company has already built up strong operating metrics, with an estimated 2026 gross margin of 84.5% and adjusted patmi margin of 47.7%, well above peers&rsquo average of 69.6% and 21.1%, respectively. &ldquo We expect its continued strong earnings growth, attractive margins and better price discovery to catalyse a valuation re-rating,&rdquo they add. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
JurongW
Elite |
12-Mar-2026 14:36
Yells: "Earnings give weight, Chart give wings" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
UltraGreen.ai Expands Asia Presence with Regulatory Approvals for IC-FlowTM Imaging System V2 in India, Thailand, Philippines, and Bangladesh Press release: https://links.sgx.com/1.0.0/corporate-announcements/0FOW8GF1F1UO3ZEP/878140_260312%20PRESS%20RELEASE%20UltraGreen.ai_IC%20Flow%20Approval%20in%20Thailand_India_Philippines_Bangladesh.pdf |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
Joelton
Supreme |
12-Mar-2026 11:32
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Newly-listed UltraGreen.ai joins three SGX &lsquo veteran&rsquo stocks on iEdge Singapore Next 50 Indices Listed on the Singapore Exchange in December 2025, UltraGreen.ai will join Haw Par Corp, GuocoLand and Valuemax Group on the iEdge Singapore Next 50 indices on Mar 23. In a press release on the indices&rsquo quarterly review, SGX announced that the afore-mentioned four counters will replace Banyan Tree Holdings, SBS Transit, Geo Energy Resource and COSCO SHIPPING International Singapore. In the previous update in December, Golden Agri-Resources, Yangzijiang Maritime Development and Centurion Accommodation REIT replaced Nanofilm Technologies International, Samudera Shipping Line and Aztech Global. The iEdge Singapore Next 50 Indices incorporate free-float, market capitalisation and liquidity criteria to identify companies that are both sizeable and tradable. To serve a broader spectrum of investor needs, the indices are available in two variants: one weighted by market capitalisation, and the other by liquidity. These indices complement existing benchmarks and are designed to raise the visibility and broaden market participation in the next cohort of 50 companies, excluding the 30 largest companies by market capitalisation. The next review will occur in June 2026. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
Joelton
Supreme |
27-Feb-2026 10:27
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
UltraGreen.ai earnings rise 35% to US$75.6 million for FY2025 Revenue climbs 24% to US$142.4 million [SINGAPORE] UltraGreen.ai on Thursday (Feb 26) posted a 36 per cent increase in net profit to US$75.6 million for the 2025 financial year, from US$56 million the year before. Its revenue was up 24 per cent on the year at US$142.4 million, from US$114.7 million. The fluorescence-guided surgery and digital health platform said the growth was driven mainly by increases in the amount of indocyanine green (ICG) &ndash a dye used in medical diagnostics &ndash sold in the Americas, as well as the average price per ICG vial. It noted that the average price per vial was higher in the United States than elsewhere, while the global average cost for each vial climbed 17 per cent year on year in FY2025. UltraGreen.ai sold its cardiac monitoring business, UltraLinQ, in August 2025, before it listed on the Singapore Exchange. Excluding the contributions from UltraLinQ, its revenue for FY2025 stood at US$137.9 million. Its full-year net profit includes US$11.8 million in exceptional items, related primarily to a gain of US$23.7 million from the sale of UltraLinQ. This was partially offset by a tax provision on dividend income amounting to US$8.5 million, as well as impairment and other charges of US$3.4 million. Among others, these impairments were linked to assets held for sale and losses on the disposal of intangible assets. The company said the outlook for ICG &ldquo remains positive&rdquo , citing more than 20,000 peer-reviewed publications and 780 clinical trials &ndash completed or ongoing &ndash that demonstrate the dye&rsquo s efficacy and clinical utility. It added that clinical adoption is growing, with regulatory approvals of Verdye &ndash an injectable form of ICG &ndash expanding to 40 countries, compared with 35 in 2024. For FY2026, UltraGreen.ai has guided for US$170 million to US$190 million in revenue. &ldquo This outlook is driven by underlying business expansion, the full-year impact of pricing initiatives implemented in FY2025, and further penetration into new markets,&rdquo said Ravinder Sajwan, the company&rsquo s chief executive officer and executive director. Shares of UltraGreen.ai : ULG -5.59% finished Thursday 5.6 per cent or US$0.10 lower at US$1.69. |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
LexLut88
Member |
27-Feb-2026 08:23
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
with a great result and potential listing at nasdaq , i see this share with a high growth potential . however , why the drop ? anyway if i have more bullet , will buy more to keep until NAsdaq listing. wishing everyone here a huat huat 2026 . | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
|
|||||||||||||||||||
|
JurongW
Elite |
26-Feb-2026 22:52
Yells: "Earnings give weight, Chart give wings" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
NPAT (before exceptional items) margin of 44.8%, with NPAT of US$63.8 million, up 14% YoY Adjusted EBITDA margin of 62.8% (US$89.4 million Adjusted EBITDA) and gross margin of 85% 13% YoY growth in vial volumes, driving robust revenue expansion FY2026 revenue forecast of US$170&ndash 190 million representing 19%-33% YoY growth Press release of full year results https://links.sgx.com/1.0.0/corporate-announcements/W7CF029RYVJ9AQUV/876386_UltraGreen.ai%20Limited%20-%20FY2025%20Results%20Release.pdf |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
n3wbie
Elite |
26-Feb-2026 15:01
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Any followers of the stock? One of the rare gems that has a growth story - let' s see how their maiden earnings turn out today after market. | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
JurongW
Elite |
19-Feb-2026 20:33
Yells: "Earnings give weight, Chart give wings" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Initiate Coverage
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
Newbie85
Veteran |
19-Feb-2026 18:55
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Can share the UOB $2 target report? | ||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
SmallSmall
Supreme |
05-Jan-2026 14:54
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
Once $1.75 breaks it will move fast towards $1.80 - $1.85 $1.74 +$0.05
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
muifan
Supreme |
05-Jan-2026 10:22
Yells: "Take the leap of faith dont regret 20 years later!" |
||||||||||||||||||
|
x 0
x 0 Alert Admin |
sky the limit $5 la
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
SmallSmall
Supreme |
05-Jan-2026 10:17
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
$1.75 first then follow by $1.80 .... $1.73 +$0.004
|
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||
|
SmallSmall
Supreme |
05-Jan-2026 10:03
|
||||||||||||||||||
|
x 0
x 0 Alert Admin |
This will be the stock to watch this year.......$1.68 -$0.01 $2.00 target by UOB KH. A very niche and important market |
||||||||||||||||||
| Useful To Me Not Useful To Me | |||||||||||||||||||